GSA Capital Partners LLP Has $1.67 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM

GSA Capital Partners LLP raised its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 91.3% during the 4th quarter, HoldingsChannel reports. The firm owned 9,117 shares of the company’s stock after purchasing an additional 4,350 shares during the quarter. GSA Capital Partners LLP’s holdings in Axsome Therapeutics were worth $1,665,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after acquiring an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after acquiring an additional 84,151 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Axsome Therapeutics in the first quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,250 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Mizuho raised their price objective on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. UBS Group raised their price objective on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Finally, Morgan Stanley raised their target price on Axsome Therapeutics from $217.00 to $242.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $251.26.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 35,378 shares of Axsome Therapeutics stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total transaction of $5,726,990.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company’s stock, valued at approximately $1,368,150. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 72,628 shares of company stock valued at $12,205,662. 20.60% of the stock is currently owned by company insiders.

Axsome Therapeutics Stock Down 0.3%

Shares of AXSM stock opened at $226.67 on Wednesday. The stock has a market cap of $11.66 billion, a P/E ratio of -60.77 and a beta of 0.59. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $235.91. The stock has a fifty day moving average price of $183.64 and a 200 day moving average price of $170.00. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The firm had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The firm’s quarterly revenue was up 57.4% compared to the same quarter last year. Analysts predict that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.